Icon to close the modal
Support
Sales
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
Modal Close Icon
Sales Form
Please fill out the form and a sales representative will get in touch with you.

Capability:

Product Line:

Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Ordering
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
Onsite Visiting
Location Icon
850 W Rio Salado Pkwy, Tempe, AZ 85281 United States
Customer Service
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
6:00 a.m. – 4:30 p.m. Arizona Time (Monday-Friday)
Fax Icon
1.800.440.5376

Covera™

Vascular Covered Stent

Proven Performance Through Innovative Design*

Contact Us navigation arrow
Carousel Image
Loading
tabs dropdown arrow
Overview
  • Helical design for radial strength and flexibility
    • Engineered for flexing, compression, and torsion with helical struts and angled bridges
  • Thumbwheel delivery facilitates accurate placement control
  • Atraumatic tip designed to facilitate smooth insertion and removal at the access site
  • Available in straight and flared configurations for optimized hemodynamic flow at the venous anastomosis
true
References

*Target Lesion Primary Patency (TLPP) of 71%, defined as the interval following the index intervention until the next clinically-driven reintervention at or adjacent to the original treatment site or until the extremity was abandoned for permanent access. Freedom from primary safety events = 96.4%, defined as freedom from any adverse events, localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death. AVeVA Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe AZ

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true

BD-23522

Products & Accessories
  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

  • product-image

    Covera™ Vascular Covered Stent

References

*Target Lesion Primary Patency (TLPP) of 71%, defined as the interval following the index intervention until the next clinically-driven reintervention at or adjacent to the original treatment site or until the extremity was abandoned for permanent access. Freedom from primary safety events = 96.4%, defined as freedom from any adverse events, localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death. AVeVA Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe AZ

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true
Resources
References

*Target Lesion Primary Patency (TLPP) of 71%, defined as the interval following the index intervention until the next clinically-driven reintervention at or adjacent to the original treatment site or until the extremity was abandoned for permanent access. Freedom from primary safety events = 96.4%, defined as freedom from any adverse events, localized or systemic, that reasonably suggests the involvement of the AV access circuit (not including stenosis or thrombosis) that require or result in any of the following alone or in combination: additional interventions (including surgery); in-patient hospitalization or prolongation of an existing hospitalization; or death. AVeVA Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe AZ

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true
Frequently Asked Questions
false
Chat with us
Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
×